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KEY POINTS 
• Flash glucose monitoring is a useful addition to standard blood glucose monitoring and can 
provide frequent, non-invasive glucose measurements in a variety of settings. 
• Hypophysectomy is the gold-standard treatment for hypersomatotropism-associated diabetes 
in cats and offers a good chance of cure of both hypersomatotropism and diabetes mellitus. 
• Toujeo® insulin glargine appears to provide a more flat, constant activity profile than other 
long-acting insulins and could be particularly effective in cats with glycemic variability. 
SYNOPSIS 
Flash glucose monitoring is a novel, non-invasive monitoring technique, which is increasingly used in 
the management of small animal diabetes. This chapter provides guidance on the use of flash 
glucose monitoring in cats and demonstrates how this technique can be utilized in a range of feline 
diabetic cases, including those in which management is proving challenging. Other aspects of 
complicated feline diabetes cases are also discussed, including management of the sick diabetic cat, 
potassium depletion myopathy and treatment options for cats with hypersomatotropism-associated 
diabetes mellitus. The use of Toujeo® insulin glargine as a promising new long-acting insulin for 
diabetic cats is also discussed. 
 
  
This article uses a case-based approach to explore the current evidence on feline diabetes mellitus 
(DM) treatment and how to best apply this evidence in clinical situations. These cases also discuss 
novel concepts in feline DM management, including flash glucose monitoring, novel insulin 
preparations, and hypophysectomy for the treatment of hypersomatotropism (HS). 
 
Case 1:  SICK DIABETIC CAT 
Monkey, 12 year old, neutered male, domestic shorthair 
Presentation: 
- Inappetence for 3 days 
- Vomited once yesterday 
- Increased thirst for 1 week 
- Depressed mentation for 1 day 
- Plantigrade gait for 1 day 
- No other recent health concerns 
Initial exam: 
- Weight: 7.8 kg 
- Body condition score (BCS): 7.5/9 
- Muscle score: 2/3 (mild muscle loss) 
- Mentation: Quiet, responsive 
- Hydration: Slightly tacky oral mucosa 
- Vital signs: Heart rate 170/min, Respiratory rate 24/min, Temperature 38.3oC 
 
TEXT BOX 1: Initial in-house clinical pathology results for Monkey 
Blood glucose (BG): 513mg/dL (reference interval [RI] 70-150mg/dL) [28.5mmol/L (RI 3.9-8.3mmol/L)] 
Plasma albumin: 4.5g/dL (RI 2.2-4.4g/dL) [45g/L (RI 22-44 g/L)] 
Plasma urea: 38.8mg/dL (RI 10.0-30.0 mg/dL) [13.6mmol/L (RI 3.6-10.7mmol/L)] 
Plasma creatinine: 2.32mg/dL (RI 0.30-2.00mg/dL) [211umol/L (RI 27-186umol/L)] 
Plasma ALT: 107U/L (RI 20-100U/L) 
Plasma ALP: 48U/L (RI 10-90U/L) 
Plasma sodium: 147mEq/L (RI 142-164mEq/L) [147mmol/L (RI 142-164mmol/L)] 
Plasma potassium: 3.9mEq/L (RI 3.7-5.8mEq/L) [3.9mmol/L (RI 3.7-5.8mmol/L)] 
Plasma chloride: 110mEq/L (RI 110-126mEq/L) [110mmol/L (RI110-126mmol/L)] 
Urine specific gravity: 1.023 
Urine glucose: 4+ 
Urine ketones: 2+ 
 
Assessment: 
- Does this cat have DM or stress hyperglycemia? 
Presence of ketosis is useful to distinguish diabetic from non-diabetic sick cats and can be more 
reliable than fructosamine.1 Although there is no information yet about blood ketones in this case, the 
presence of ketonuria indicates that ketosis and therefore DM is likely. Semi-quantitative blood/serum 
ketone measurement can be easily performed by applying a drop of serum or plasma to the ketone 
test patch of a urine dipstick, which provides a colorimetic indication of acetoacetate ± acetone 
concentration.2 Point-of-care handheld ketone meters, which measure β-hydroxybutyrate are also 
reliable in cats. These are likely to be more sensitive for the detection of ketosis due to β-
hydroxybutyrate being the predominant ketone body in ketosis secondary to DM. They also provide a 
rapid, quantitative measurement, which can be used to monitor patient progress.3,4  
- Is there ketoacidosis (DKA) and/or hyperosmolality? 
Although ketosis is likely, identification of decreased blood pH and/or decreased plasma bicarbonate 
concentration is required to diagnose acidosis. However, when this is unavailable, the European 
Society of Veterinary Endocrinology ALIVE guidelines recommends that diabetic patients who are 
unwell “should be suspected of suffering from DKA”.5 Diabetic cats that are inappetent or anorexic 
should be assumed to be unwell because DM generally causes polyphagia, unless complicated by 
another condition. 
Estimated osmolality is 344mOsm/kg (Text Box 2). Patients are considered hyperosmolar at an 
osmolality >320mOsm/kg, whereas the more complicated Hyperosmolar Hyperglycemic State (HHS) 
is usually associated with osmolality >340 mOsm/kg and BG >600mg/dL (>33mmol/L).6 
Therefore, Monkey should commence treatment for DKA and possible HHS. Treatment for these two 
conditions is similar and, although it will be useful to have additional diagnostic information in due 
course, there is already sufficient information to begin treatment without delay. Importantly, DKA in 
cats with newly-diagnosed DM does not affect survival time,7 and these cases can often go on to 
achieve diabetic remission.8 One important negative prognostic indicator in cats with newly diagnosed 
DM is higher plasma creatinine concentration.7 It is therefore noteworthy that Monkey’s creatinine is 
only mildly increased, despite dehydration and hyperosmolality. Although it is difficult to assess renal 
function in diabetic cats with dehydration and osmotic diuresis, chronic kidney disease is not more 
frequent than in non-diabetic cats.9 
 
TEXT BOX 2: Estimation of Plasma Osmolality 
Estimated Osmolality (mOsm/kg) = 2*(Na+ + K+) + glucose(mg/dL)/18 + BUN(mg/dL)/2.8 
[or 2*(Na+ + K+) + glucose(mmol/L) + BUN(mmol/L)] 
The main determinant of osmolality is sodium; glucose has less impact unless there is severe 
hyperglycemia. Therefore, effective osmolality can alternatively be calculated using the simplified 
formula: 
Effective Osmolality = 2*Na+ + glucose(mg/dL)/18 [or 2*Na+ + glucose(mmol/L)] 
 
Goals of treatment in sick diabetic cats: 
- Gradually replace body fluid deficit 
- Slowly decrease plasma osmolality and BG concentration 
- Halt and prevent ketogenesis 
- Restore electrolyte and acid-base balance 
- Identify and manage any underlying or precipitating factors 
Fluid and electrolyte therapy: 
- No published studies have compared the efficacy of different fluid types in sick diabetic cats, but 
0.9% saline or lactated Ringer’s solutions are commonly recommended.6,10,11 
- A conservative fluid rate is recommended to avoid over-hydration and major osmotic shifts. Flow 
rates 1.5-2 times normal maintenance requirements (4-6mL/kg/hr) are therefore appropriate. This 
aligns with the current perspective for human pediatric patients with DKA that advocates a “one 
size fits all” strategy with slow and even correction of fluid deficit.12 
- It is important to calculate rates based on estimated ideal body weight in underweight or 
overweight cats. As Monkey has an overweight body condition, it is prudent to use an estimation 
of ideal body weight (e.g. 5.5kg) for all dose calculations. 
- Maintenance fluids should be supplemented with 30-40mEq/L (30-40mmol/L) of potassium (KCl 
or a 50:50 combination of KCl and KPO4) from the outset. Sick diabetic cats have a high risk of 
hypokalemia even if plasma potassium concentration is not decreased at presentation. Potassium 
depletion results from reduced intake due to anorexia, increased loss due to vomiting and 
diuresis. Fluid therapy causes dilution of circulating potassium concentrations and promotes 
further renal loss, while insulin therapy and correction of acidosis results in movement of 
potassium out of the extracellular space into cells. In critically ill patients, adjustment of fluid 
potassium supplementation should ideally be based on results of plasma potassium concentration 
monitoring.6,11 Such intensive monitoring is usually not required for cats that rapidly recover a 
normal or polyphagic appetite while treated with fluids supplemented with potassium as 
recommended above. 
Insulin therapy: 
- Insulin treatment should commence as soon as practical. Cats with DKA recover more rapidly if 
insulin treatment commences within 6 hours after admission13 and higher concentrations of 
intravenous (IV) insulin result in better clinical outcomes.14 Although fluid therapy will correct 
many metabolic derangements and cause BG to decrease, it won’t switch off ketogenesis which 
is the catalyst for DKA. In fact, before insulin was commercially available, DKA was almost 
uniformly fatal. 
- Rapid-acting insulin, such as regular (soluble) insulin, can be administered as an IV constant rate 
infusion (CRI) or as repeated intramuscular (IM) and subcutaneous (SC) injections.6,10,11 Other 
rapid-acting options are insulin lispro15 and aspart.16 If rapid-acting insulin is unavailable, Lantus® 
glargine can be substituted in CRI protocols as it has a similar action to regular insulin when 
delivered IV.17 
- CRI protocols are often simpler and less labor intensive for prolonged management of sick 
diabetic cats. The main constraint is that a separate fluid infusion pump is required in addition to 
that used for supportive fluid therapy. Text Box 3 and Figure 1 provide a simple, “one size fits all” 
insulin CRI protocol that will be appropriate for Monkey. 
- Protocols of repeated IM and SC injections are also effective. The most common protocol 
comprises an initial 0.2U/kg dose of regular insulin administered IM and followed with SC doses 
at 0.1U/kg every hour. Ongoing insulin doses are then adjusted based on BG monitoring at least 
once hourly.18 
- Glargine can also be used IM and SC for the management of sick diabetic cats.19,20 A protocol 
using intermittent IM/SC injections of glargine and regular insulin was established as an 
alternative to insulin CRI for treatment of DKA in cats.20 Glargine was administered at a dose of 
0.25U/kg q12hrs. Blood glucose was checked q2-4hrs and the following actions taken: 
o 1 U regular insulin was administered q6hrs when BG was >250mg/dL (>14mmol/L) 
o 2.5% glucose CRI was given when BG was 80-250mg/dL (4.4-13.8mmol/L) 
o an IV bolus of glucose plus ongoing CRI with 5% glucose was given if BG was <80mg/dL 
(<4.4mmol/L).20 
 
TEXT BOX 3: “One size fits all” insulin CRI protocol for sick diabetic cats 
- Add 25U (0.25mL) regular insulin to 500mL saline or lactated Ringer’s solution (or 50U (0.5mL) to 
1000mL solution), resulting in a 50mU/mL solution. Cover the fluid bag to protect insulin from 
light. 
- Priming the line is unnecessary. Some insulin will adsorb to the lining of the infusion bag and 
giving set, but this soon reaches steady state and all remaining insulin is delivered to the animal. 
It is also not necessary to run the insulin CRI through a separate IV catheter. In fact, it is prudent 
to run concurrent insulin and glucose infusions through the same catheter to ensure that both 
infusions cease at the same time if the catheter fails. 
- An initial insulin infusion rate of 50mU/kg/hr is recommended, achieved by administering the 
above solution at 1mL/kg/hr (calculated using estimated ideal body weight). 
- This rate is halved to 25mU/kg/hr (0.5mL/kg/hr of this solution) when BG reaches 180-270mg/dL 
(10-15mmol/L). At the same time, maintenance fluids should be changed to contain 2.5% 
dextrose in 0.45% saline supplemented with 30-40mEq/L (30-40mmol/L) potassium. 
- A reliable means of achieving a fairly stable BG concentration in an anorexic diabetic cat is to 
balance IV infusion of insulin at 25mU/kg/hr (0.5mL/kg/hr) with 2.5% dextrose in 0.45% saline 
supplemented with potassium at 6mL/kg/hr. This is the safest option whenever close monitoring is 
not possible. 
- Insulin infusion rate is adjusted up or down to maintain BG at 145-270mg/dL (8-15mmol/L). If the 
cat’s illness is associated with substantial insulin resistance (IR), an insulin infusion rate of up to 
150mU/kg/hr (3mL/kg/hr of the solution described above) may be required to maintain BG at 145-
270mg/dL (8-15mmol/L). 
- When a previously anorexic diabetic cat begins to eat, the IV insulin rate might need to be 
increased to manage increased glycemia. 
- See Figure 1 for an example flow chart for hospital use. 
 
Glucose monitoring: 
- The standard method for monitoring glucose response to treatment is serial measurement of BG 
concentration. Blood samples can be obtained by direct venipuncture, although use of a central 
venous catheter or the marginal ear vein are typically more comfortable and less stressful for the 
cat.10 
- Veterinary glucose meters that have been validated using feline samples are recommended for 
monitoring sick diabetic cats, although meters intended for human use can also be reliable.21-23 
- Continuous glucose monitors (CGMs) measure interstitial glucose and can supplement traditional 
BG measurement in hospitalized cats.24 CGMs may be less accurate in cats when there is 
hypoglycemia,25 but importantly can detect low glucose values that would have been missed by 
intermittent BG testing.26 The working range of these systems is not a practical limitation in the 
clinical setting. For treatment decisions, it is usually sufficient to know that an animal’s glucose 
concentration is <40mg/dL (<2.2mmol/L) or >400mg/dL (>22.2mmol/L). in this situation, blood 
glucose measurement can be performed if a more accurate result is required. 
- The Abbott® Freestyle Libre® glucose monitoring system is an innovative and relatively 
inexpensive means of monitoring interstitial glucose that is simple to use.27 The Freestyle Libre® 
system consists of an adhesive sensor, which samples interstitial glucose concentration every 
minute and stores these readings for up to 8hrs (Figure 2). Whenever the sensor is scanned with 
the provided scanner, or smartphone App, a ‘flash’ of the current and previous 8hrs of interstitial 
glucose data are obtained and a trend arrow is displayed to show whether glucose is increasing, 
decreasing, or changing slowly. The system requires no calibration and each sensor will last up to 
14 days, although sensor life is typically shorter in cats. 
- Treatment decisions should not be based solely on interstitial glucose monitoring results. Instead, 
the Freestyle Libre® can identify changing glucose trends that can be confirmed by standard BG 
testing and thereby facilitate timely treatment decisions. If used correctly, flash glucose monitoring 
can thus improve patient comfort by decreasing needle sticks whilst also reducing staff workload. 
Text Box 4 provides tips for use of Freestyle Libre® flash glucose monitoring in sick diabetic cats. 
 
 
TEXT BOX 4: Tips for use of Freestyle Libre® glucose monitoring in hospitalized diabetic cats 
- A Freestyle Libre® glucose sensor should be applied as soon as practical after hospital 
admission. This allows glucose monitoring during hospitalization and also for several days after 
discharge. 
- Interstitial and BG results must be clearly differentiated on hospital charts. Two separate 
columns/rows are therefore required. 
- The system does not provide alarms for high or low glucose so must be actively monitored. For 
example, a veterinarian may write an order to “decrease the insulin CRI rate to 2mL/hr when the 
blood glucose is <270mg/dL (<15mmol/L)”. A technician can then periodically scan the sensor q1-
2hrs without disturbing the cat and record the times and glucose results on the patient’s chart. 
Once interstitial glucose concentration decreases to <270mg/dL (<15mmol/L), this can be 
confirmed by testing BG and the insulin treatment adjusted. 
- It is helpful to pay attention to the trend arrows and review the graph displayed on the device’s 
reader. 
- Any unexpected interstitial glucose results should be checked against BG concentration. 
- Once q24hrs, it is helpful to use the Freestyle Libre® software or LibreView® to generate a 
detailed PDF report and attach this to the patient’s file so it can be readily accessed by the 
veterinarian when reviewing overall progress. 
 
Outcome: 
- Monkey improved rapidly with fluid and insulin therapy, along with SC maropitant to manage 
nausea. When hematology, biochemistry, and urinalysis results were returned from the external 
reference laboratory, they did not identify any significant concurrent problems. He regained a 
polyphagic appetite within 12hrs and was discharged home after 24hrs with q12hr long-acting 
insulin therapy for maintenance, The Freestyle Libre® sensor remained in place to provide 
glucose monitoring and helpful feedback to his owners as they became accustomed to the home 
treatment regimen. 
- Monkey continued to have a weak hind leg gait at home, which progressed to generalized 
weakness unassociated with hypoglycemia. Oral potassium gluconate supplementation resulted 
in rapid resolution of severe weakness, although a mild plantigrade gait persisted. Potassium 
depletion myopathy is an important differential diagnosis in cats for both diabetic neuropathy and 
hypoglycemia. Factors that promote potassium depletion in diabetic cats include polyuria and 
insulin treatment.28 Improvement in response to oral potassium gluconate supplementation 
typically occurs within 1-2 days with full recovery within 2-3 weeks.29 
- Monkey achieved diabetic remission that lasted for many years after 7 weeks of insulin treatment. 
- The residual plantigrade gait presumably due to diabetic neuropathy gradually resolved by 3 
months. 
- He steadily lost weight and achieved an ideal body weight of 5.5kg after 5 months. 
 
Case 2:  CAT WITH HYPERSOMATOTROPISM-ASSOCIATED DM 
Bonnie, 11 year old, female neutered, domestic longhair 
Presentation 
- DM diagnosed 4 months previously and treated with q12hr Lantus® insulin glargine since 
diagnosis 
- Persistently poor glycemic control, despite increasing insulin dosage 
- Obvious polyuria and polydipsia (PUPD), and extreme polyphagia. Overweight with minimal 
weight loss (200g) since diagnosis 
- Currently receiving 10U (1.8U/kg) glargine q12hrs and fed a carbohydrate-restricted, wet 
commercial diet 
- Recent serum fructosamine 680µmol/L (RI 249-320µmol/L) 
- Home blood glucose measurements persistently >360mg/dL (>20mmol/l) throughout the day 
- Presented for assessment of IR 
 
Examination 
- See Figures 3a and b for patient photograph and oral examination 
- Weight: 5.5kg 
- BCS: 6/9 
- Muscle condition score: 2/3 (mild muscle loss) 
- Alert, appropriate mentation 





It is vital to first exclude problems of insulin administration and/or storage when assessing cats with 
apparent IR. These were excluded in Bonnie’s case. Many concurrent conditions can contribute to IR 
in feline diabetics (Text Box 5), but several features make hypersomatotropism (HS) a likely cause in 
Bonnie’s case. Hypersomatotropism can cause particularly profound IR compared to other 
comorbidities, which is consistent with Bonnie’s persistent, marked hyperglycemia, despite substantial 
insulin dosing. Extreme polyphagia, as seen in Bonnie, is a common finding in cats with HS.30 
Bonnie’s subjective facial broadening and prognathism inferior (Figure 2a and 2b) suggest she is 
affected by acromegaly, which results from the mitogenic effects of excess growth hormone (GH). 
However, only a proportion of cats with HS-associated DM have noticeable acromegaly and its 
absence should not exclude the possibility of HS.30,31 Index of suspicion for HS would be particularly 
great if practicing in a country with a relatively high reported prevalence of HS among diabetic cats. 
Hypersomatotropism has been estimated to cause approximately 25% of feline DM cases in the 
United Kingdom.30 However, this could be an overestimation due to veterinarians’ being more likely to 
submit samples for the study’s free IGF-1 measurement from cats with possible signs of HS. An 
alternative study from Switzerland and the Netherlands reported an estimated prevalence of 17.8% 
among diabetic cats.32 
 
Serum insulin-like growth factor-1 (IGF-1) measurement was submitted and was supportive of HS 
(239nmol/L [1825ng/mL]; RI <130nmol/L [<1000ng/mL]). 
 





Exogenous glucocorticoids or progestogens 
Pancreatitis 
Chronic kidney disease 
Gastrointestinal disease 
Any chronic inflammatory disease 
 
Are further diagnostic tests necessary to confirm HS? 
A serum IGF-1 concentration of >130nmol/L (>1000ng/mL) has a positive predictive value of 95%30 
for HS so, in combination with Bonnie’s consistent clinical findings, is highly suggestive of HS. 
Pituitary imaging with computed tomography (CT) or, less often, magnetic resonance imaging (MRI) is 
often used to support the diagnosis by demonstrating pituitary enlargement. Despite this, 3-4% of 
cases have a normal pituitary size on diagnostic imaging30 and this percentage is likely to increase 
with improved awareness and earlier detection of cats with HS. Hypersomatotropism should therefore 
not be excluded based on a normal pituitary appearance on advanced imaging. Pituitary imaging also 
provides information which is relevant to several treatment modalities (Table 1). 
 
What are the major treatment options for HS-associated DM? 
Table 1 shows the main treatment options for HS-associated DM in cats.  
 
Treatment Plan 
Bonnie underwent hypophysectomy to provide the greatest chance of cure of HS and resolution of 
DM. Pre-operative cranial computer tomography revealed moderate pituitary enlargement 
(ventrodorsal height 8mm, normal ≤4mm33) (Figure 4). The extent of acromegalic cardiomyopathy was 
assessed pre-operatively using echocardiography in order to guide anesthesia and perioperative fluid 
therapy.  
 
Pre-operatively, an Abbott® Freestyle Libre® flash glucose monitoring system was applied to provide 
frequent, non-invasive interstitial glucose measurement during the perioperative period (Figure 5). 
Hypophysectomy was performed via a transsphenoidal approach through the oral cavity (Figure 6).34 
 
What are the medical considerations following hypophysectomy? 
- To control hyperglycemia, cats receive a CRI of 0.9% NaCl with soluble insulin ± dextrose 
from anesthesia induction until willing to eat post-operatively, when long-acting maintenance 
insulin can be reintroduced. At the author’s (RG) hospital, a maximum hourly rate of 
4mL/kg/hr for all infusions is used to limit risk of volume overload. Cats often eat within 24hrs 
post-surgery. Insulin sensitivity can rapidly improve following successful surgery (Figure 7) so 
glucose concentration must be frequently monitored and insulin dose adjusted. Maintenance 
insulin is typically re-started at a reduced dose compared to pre-operatively due to improved 
insulin sensitivity. 
- Treated cats require lifelong glucocorticoid and thyroxine supplementation due to absolute 
lack of adrenocorticotrophic hormone and thyroid stimulating hormone, respectively, following 
hypophysectomy. A hydrocortisone sodium succinate CRI is started immediately before 
pituitary removal and is continued post-operatively until oral glucocorticoid therapy can be 
introduced. Oral levothyroxine is started once cats can tolerate oral medication.  
- Antidiuretic hormone (ADH) supplementation is required at time of surgery and 
postoperatively to treat central diabetes insipidus because hypophysectomy causes cessation 
of ADH secretion by the neurohypophysis. Supplementation can eventually be discontinued in 
some cats because ADH from the hypothalamus can still be secreted into the systemic 
circulation via the portal capillaries of the median eminence,35 
- Prophylactic amoxicillin-clavulanate therapy is given for 2 weeks postoperatively. 
 
Outcome 
Bonnie’s hypophysectomy proceeded without complication and she was alert and willing to eat within 
18hrs of surgery. Conjunctival desmopressin (1 drop q8hr) was started during surgery. 
Hydrocortisone CRI was replaced with oral hydrocortisone (0.5mg/kg q12hr) the day following 
surgery. Oral levothyroxine (0.1mg total dose q24hr) and a reduced dose of Lantus® glargine (3U 
q12hr) was introduced 2 days after surgery. Insulin sensitivity noticeably improved during post-
operative hospitalization (Figure 7) and Bonnie was discharged 1 week post-surgery on a Lantus® 
glargine dose of 1U SC q12hr. Hydrocortisone dose was reduced to 0.5mg/kg q24hr at the time of 
discharge. One month post-operatively, IGF-1 measurement revealed resolution of 
hypersomatotropism (8.4nmol/L [64ng/mL]), and a serum total thyroxine measurement five hours 
post-pill was 55nmol/L (RI 19-65nmol/L) [4.3 µg/dL (RI 1.5-5.0µg/dL)], supporting adequate 
levothyroxine supplementation. Bonnie was able to discontinue insulin therapy 3 weeks after surgery 
and went on to achieve sustained diabetic remission. Conjunctival desmopressin frequency was 
reduced over 3 months following surgery, but discontinuing treatment resulted in PUPD. Therapy was 
therefore re-instated and continued at 1 drop q24hr indefinitely.  
 
Case 3:  EXCESSIVE GLYCEMIC VARIABILITY IN A DIABETIC CAT 
Mu, 16 year old, neutered female Burmese 
Presentation: 
- DM first diagnosed 6 years ago; remission readily achieved within a few months 
- DM relapsed 2 years ago and Mu subsequently remained insulin-dependent 
- Stable glycemic control has been difficult to achieve over the last year, despite careful adjustment 
of insulin dose and Mu has experienced several unexpected episodes of hypoglycemia with mild 
to severe clinical signs. 
- Insulin treatment was changed 9 months ago from veterinary porcine lente insulin 
(Vetsulin/Caninsulin®) administered q12hr with U-40 syringes to Lantus® glargine insulin 
administered q12hr with a Solostar® insulin dosing pen. Current dose is 1U q12h. 
- BG monitoring at home is limited because the owner works long hours. In addition to occasional 
hypoglycemia, results over several months also frequently identified both moderate and severe 
hyperglycemia (range 30-685mg/dL, 1.7-38mmol/L). 
- Mu has a stable body weight, but is often PUPD, and has polyphagia. Urine dipstick testing at 
home is usually positive for glucose, but a negative result is obtained about once weekly. 
 
Examination: 
- Weight: 4.7kg 
- BCS: 6/9 
- Muscle score: 3/3 
- Mentation: Alert, appropriately responsive 
- Unremarkable physical exam with a soft glossy coat. 
 
Assessment: 
- Several features of Mu’s case are consistent with excessive “glycemic variability”,36 a condition 
which anecdotally appears to be more common in cats with long duration of DM. 
- “Somogyi effect” is also often used to explain periods when both hypoglycemia and 
hyperglycemia occur. A more appropriate term which has been adopted in human medicine is 
“glycemic variability.”36-38 The term ‘brittle’ DM has also been used, although this is now less 
preferred. 
- A key observation is failure of increased insulin doses to resolve hyperglycemia. Instead the cat 
continues to have poor diabetic control with higher insulin doses but might become prone to 
unexpected hypoglycemia. Decreasing insulin dose sometimes results in improvement of clinical 
signs, especially if the dose was relatively high,39 but often the outcome of insulin dose reduction 
is lower risk for hypoglycemia but persistence of poor diabetic control. Fluctuation between 
hyperglycemia and hypoglycemia often appears to follow a 3-day cycle. 
- Availability of CGM has provided insight in human diabetics that was not possible from 
intermittent BG measurements. Individuals with increased glycemic variability present with poor 
diabetic control due to the occurrence of frequent hyperglycemia, whereas most of the 
hypoglycemic events are associated with no clinical signs and would be missed by standard 
intermittent BG monitoring. Nevertheless, the frequent hypoglycemia can induce physiologic 
unawareness of hypoglycemia and impaired glucose counter-regulation, which in turn 
predisposes to increased risk of neuroglycopenia.40 Whereas the periods of hypoglycemia are 
likely caused by excess exogenous insulin, the mechanism(s) for the periods of hyperglycemia 
are poorly understood and probably relate to the multiple causes of hyperglycemia and IR in DM. 
- Longer-acting insulin preparations are generally recommended for treatment of DM in cats.41-43 
because they typically result in less potent and more prolonged duration of action than 
intermediate-acting products. Recently, a new 300U/mL glargine insulin product (Toujeo®) was 
shown to have a significantly longer and more ‘flat’ time-action profile44 than any other product, 
and early use in clinical cases has resulted in very good outcomes.45 Therefore, Toujeo® glargine 
might provide benefit for cats with excessive glycemic variability. 
 
Treatment and Outcome: 
- An Abbott® Freestyle Libre® flash glucose monitoring system was applied to side of the neck to 
provide more information on glucose excursions overnight and while Mu’s owner was at work. 
The sensor was covered by a loose ‘scarf’ around the neck (Figure 8). Treatment with 1U q12hr 
Lantus® glargine insulin was continued. The owner compared interstitial and blood glucose 
measurements whenever convenient. Marked glycemic variability was confirmed with glucose 
ranging <40 to >400mg/dL (<2.2 to >27.8mmol/L) over the first 4 days (Figure 9). No clinical signs 
due to hypoglycemia were observed during this period. 
- After 4 days, treatment was changed to 1U q12h glargine 300 U/mL insulin administered with the 
pre-filled Toujeo® SoloStar® Pen (Figure 10). Gradual smoothing out of the interstitial glucose 
curve was observed over the next 4 days (Figure 11). 
- Mu improved with resolution of PUPD and polyphagia over the first week. On 2 occasions during 
the first 6 weeks of treatment with Toujeo® insulin, hypoglycemia with mild clinical signs occurred. 
The signs were much less severe than the owner was accustomed to so the episodes initially 
went unrecognized. The dose of Toujeo® insulin was decreased first to 1U q24hr and then to 1U 
q48hr, and Mu then maintained good diabetic control on the latter dose with no further clinical 
signs of hypoglycemia for many months. 
 
Summary 
Flash glucose monitoring allows frequent glucose monitoring in diabetic cats while avoiding patient 
discomfort, and therefore provides a useful tool in the management of diabetic cats, especially those 
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Figure 1: Example of a fluid therapy flow chart for use in hospitalized diabetic cats. Diagram author’s 
(LF’s) own. 
 
Figure 2: A Maine Coon with an adhesive glucose sensor for a flash CGM placed on its epaxial area 
(left). The sensor can be scanned to download glucose data (right). 
 
Figure 3: Patient photographs demonstrating subjectively broad facial features (a) and prognathism 
inferior (b). 
 
Figure 4: Transverse cranial computed tomography image showing pituitary enlargement. 
 
Figure 5: A flash glucose sensor is applied to Bonnie’s lateral thoracic wall. Small drops of tissue glue 
are applied to the adhesive layer for additional security. 
 
Figure 6: Patient is positioned (prior to draping) for transsphenoidal hypophysectomy 
 
Figure 7: Interstitial glucose curves, generated using a flash CGM system, before (a) and 5 days’ after 
(b) hypophysectomy, showing greatly improved insulin sensitivity (images courtesy of Dr. J. Cockerill, 
Eaton Bunbury Veterinary Clinic, permission obtained July 26th 2019) 
 
Figure 8: A loose ‘scarf’ (middle and right) can protect a flash CGM sensor applied to the side of the 
neck (left) and so extend the life of sensors worn in the home environment. 
This is simply fashioned by pinning together the top and toe of a sock around the neck. 
 
Figure 9: Interstitial glucose curves from Case 3, generated using a flash CGM system and 
demonstrating excessive glycemic variability ranging <40 to >400 mg/dL (<2.2 to >27.8 mmol/L. 
 
Figure 10: Side by side comparison of the 300 U/mL glargine (left in each picture) and 100 U/mL 
glargine (right in each picture) insulin dosing pens. Note all staff and clients must be educated to 
never to draw the 300 U/mL insulin from the dosing pen using a syringe. 
 
Figure 11: Interstitial glucose curves generated using a CGM system on a cat with excessive glycemic 
variability and a history of unexpected episodes of neuroglycopenia. The change from 100U/mL 
Lantus® glargine to 300U/mL Toujeo® glargine insulin at the same dose occurred on Monday March 
19. Glycemic variability then subjectively reduced and the average daily interstitial glucose decreased 





Table 1: Main treatment Options for Cats with HS-associated DM 
Treatment Rationale Advantages and Disadvantages 
Standard DM 
management only  
Attempts to manage the diabetogenic 
effects of GH excess only 
Advantages 
- Widely-accessible option 
- Might maintain an acceptable quality of life for a period of 
time 
Disadvantages 
- Does not treat the pituitary tumor or mitogenic effects of 
GH e.g. acromegalic changes 
- DM control often poor with severe ongoing DM signs 
- Large insulin doses potentially required, which can be 
costly 
- Large insulin dosage makes hypoglycemic episodes 
possible when pulsatile GH secretion is low 
Radiotherapy Targeted radiation energy 
preferentially damages pituitary 
tumor tissue 
Several protocols described 
including, recently, stereotactic46-48 
Advantages 
- Improved DM control common, with 30-40% diabetic 
remission rate 
- Might shrink tumor so improve any neurological signs 
Disadvantages 
- Typically weeks-months for improvement to become 
apparent 
- IGF-1 and mitogenic effects of GH do not normalize 
- Relapse common 
- Limited availability 
- Costly 
- Repeated anesthesia required (fewer with stereotactic) 
Hypophysectomy Surgical pituitary removal Advantages49 
- Removes tumor  
- Normalization of IGF-1 and cure of HS in >90% of cats 
- Approximately 70% DM remission rate 
Disadvantages 
- Very limited availability 
- Costly 
- Associated mortality (<10%) 
- Long-term hormonal replacement required 
Cryohypophysectomy Surgical cryoablation of the pituitary 
gland 
Advantages 
- Destroys tumor tissue 
- Decreased IGF-1 in the only 2 cases reported50,51 
Disadvantages 
- Little clinical experience, limited availability 
- Costly 
Pasireotide  Injectable somatostatin analogue. 
Inhibits GH secretion from pituitary 
tumor 
Advantages 
- Improved DM control common, with diabetic remission 
rates of approximately 20-25%52 
- Generally well-tolerated 
Disadvantages 
- IGF-1 and mitogenic effects of GH do not normalize 
- Does not treat tumor 
- Limited availability 
- Costly 
- Self-limiting diarrhea common 
Cabergoline Dopamine agonism causing inhibition 




- Generally well-tolerated 
Disadvantages 
- Little clinical experience. Might improve glycemic control 
in individual cats at dose of 5-10μg/kg PO SID.53 Further 
research warranted.  
 
